Bevacizumab is a monoclonal antibody used in the treatment of various cancers, including metastatic breast cancer and colorectal cancer. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for tumor angiogenesis. By blocking VEGF, Bevacizumab effectively starves tumors of their blood supply, slowing their growth and spread. In summary, it is a critical component of targeted cancer therapies.
Bevacizumab binds to VEGF, preventing its interaction with VEGF receptors on endothelial cells, thus inhibiting angiogenesis and tumor growth.
No published brands for this salt yet.